Intero Biosystems, Inc.
Biotechnology company developing human induced-pluripotent-stem-cell (iPSC)–derived intestinal organoid platforms for preclinical drug discovery and development. Founded in 2024 as a university spin-out, the organization focuses on producing biologically representative miniature human intestines that include multiple supporting cell types to improve translational predictability and reduce reliance on animal-only models.
Industries
N/A
Products
GastroScreen (iPSC-derived human intestinal organoid platform)
A human intestinal mini-organ system that includes epithelial lining plus supporting tissues (neurons, vasculature, muscle) intended for preclinical safety, efficacy, and disease-modeling studies.
GastroScreen (iPSC-derived human intestinal organoid platform)
A human intestinal mini-organ system that includes epithelial lining plus supporting tissues (neurons, vasculature, muscle) intended for preclinical safety, efficacy, and disease-modeling studies.
Services
Custom organoid model development
Collaborative development of donor-specific or disease-specific intestinal organoid models, including co-culture integrations and custom assay configurations.
Preclinical testing services using human intestinal organoids
Provision of organoid-based testing for safety, toxicology, and efficacy endpoints compatible with imaging, molecular assays, and functional readouts.
Supply of live or frozen organoid vials
Distribution of live or cryopreserved organoid vials delivered ready for experimentation or with defined recovery timelines post-thaw.
Custom organoid model development
Collaborative development of donor-specific or disease-specific intestinal organoid models, including co-culture integrations and custom assay configurations.
Preclinical testing services using human intestinal organoids
Provision of organoid-based testing for safety, toxicology, and efficacy endpoints compatible with imaging, molecular assays, and functional readouts.
Supply of live or frozen organoid vials
Distribution of live or cryopreserved organoid vials delivered ready for experimentation or with defined recovery timelines post-thaw.
Expertise Areas
- Organoid platform development
- iPSC differentiation and culture
- Preclinical drug safety and toxicology testing
- Preclinical efficacy and mechanism-of-action assessment
Key Technologies
- iPSC-derived organoids
- Microphysiological / organ-on-chip-style organoid systems
- Perfusable vascular network formation
- Enteric nervous system and motility assays